The Experts below are selected from a list of 60 Experts worldwide ranked by ideXlab platform
G. Alexander Patterson - One of the best experts on this subject based on the ideXlab platform.
-
Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 ameliorates acute Lung Graft Rejection
The Journal of thoracic and cardiovascular surgery, 2005Co-Authors: Takashi Suda, Niccolò Daddi, Tsutomu Tagawa, Samer A. Kanaan, Benjamin D. Kozower, Jon H. Ritter, G. Alexander PattersonAbstract:Objective Multiple gene transfer might permit modulation of concurrent biochemical pathways involved in acute Lung Graft Rejection. We investigated whether gene cotransfection into the recipient reduces acute Lung Graft Rejection. Methods Brown Norway rats were used as donors, and F344 rats were used as recipients. Recipient animals were injected with saline (groups I/VI) or 1 × 10 10 pfu of adenovirus encoding β-galactosidase (groups II/VII), transforming growth factor β1 (groups III/VIII), interleukin 10 (groups IV/IX), or both transforming growth factor β1 and interleukin 10 (groups V/X) into both leg muscles 2 days before transplantation (groups I-V) or at the time of harvest (groups VI-X). The Kruskal-Wallis test for Rejection score and 1-way analysis of variance were used to compare groups. Results Oxygenation was significantly improved in the cotransfected groups treated 2 days before transplantation and at the time of harvest. Rejection scores were also reduced in the cotransfected groups. In group V cotransfection suppressed endogenous interleukin 2 but not interferon γ and tumor necrosis factor α. Conclusion Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 suppressed interleukin 2 expression and provided a synergistic effect that reduced acute Lung Graft Rejection. This approach might be applied to the clinical setting because transplant recipients could be treated at the time of implantation.
-
Recipient intramuscular gene transfer of active transforming growth factor-β1 attenuates acute Lung Rejection
The Annals of thoracic surgery, 2001Co-Authors: Takashi Suda, Niccolò Daddi, Jon H. Ritter, Franco D’ovidio, Thalachallour Mohanakumar, G. Alexander PattersonAbstract:Abstract Background . Gene transfer into the donor Graft has been demonstrated to be feasible in reducing ischemia-reperfusion injury and Rejection in Lung transplantation. This study was undertaken to determine whether intramuscular gene transfer into the recipient can also reduce subsequent Lung Graft Rejection. Methods . Brown Norway rats served as donors and F344 rats as recipients. Recipient animals were injected with 10 10 plaque-forming units of adenovirus encoding active transforming growth factor β1 (group I, n=6), β-galactosidase as adenoviral controls (group II, n=6), or normal saline without adenovirus (group III, n=6) into both gluteus muscles 2 days before transplantation. Gene expression was confirmed by enzyme-linked immunosorbent assay. Graft function was assessed on postoperative day 5. Results . Successful gene transfection and expression were confirmed by the presence of active transforming growth factor β1 protein in muscle and plasma. Oxygenation was significantly improved in group I (group I vs II and III, 353.6 ± 63.0 mm Hg vs 165.7 ± 39.9 and 119.1 ± 41.5 mm Hg; p = 0.02 and 0.004). The muscle transfected with the transforming growth factor β1 showed granulation tissue with fibroblast accumulation. Conclusions . Intramuscular adenovirus-mediated gene transfer of active transforming growth factor β1 into the recipients attenuates acute Lung Rejection as manifested by significantly improved oxygenation in transplanted Lung alloGrafts. This intramuscular transfection approach as a cytokine therapy is feasible in transplantation and may be useful in reducing Rejection as well as reperfusion injury.
Takashi Suda - One of the best experts on this subject based on the ideXlab platform.
-
Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 ameliorates acute Lung Graft Rejection
The Journal of thoracic and cardiovascular surgery, 2005Co-Authors: Takashi Suda, Niccolò Daddi, Tsutomu Tagawa, Samer A. Kanaan, Benjamin D. Kozower, Jon H. Ritter, G. Alexander PattersonAbstract:Objective Multiple gene transfer might permit modulation of concurrent biochemical pathways involved in acute Lung Graft Rejection. We investigated whether gene cotransfection into the recipient reduces acute Lung Graft Rejection. Methods Brown Norway rats were used as donors, and F344 rats were used as recipients. Recipient animals were injected with saline (groups I/VI) or 1 × 10 10 pfu of adenovirus encoding β-galactosidase (groups II/VII), transforming growth factor β1 (groups III/VIII), interleukin 10 (groups IV/IX), or both transforming growth factor β1 and interleukin 10 (groups V/X) into both leg muscles 2 days before transplantation (groups I-V) or at the time of harvest (groups VI-X). The Kruskal-Wallis test for Rejection score and 1-way analysis of variance were used to compare groups. Results Oxygenation was significantly improved in the cotransfected groups treated 2 days before transplantation and at the time of harvest. Rejection scores were also reduced in the cotransfected groups. In group V cotransfection suppressed endogenous interleukin 2 but not interferon γ and tumor necrosis factor α. Conclusion Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 suppressed interleukin 2 expression and provided a synergistic effect that reduced acute Lung Graft Rejection. This approach might be applied to the clinical setting because transplant recipients could be treated at the time of implantation.
-
Recipient intramuscular gene transfer of active transforming growth factor-β1 attenuates acute Lung Rejection
The Annals of thoracic surgery, 2001Co-Authors: Takashi Suda, Niccolò Daddi, Jon H. Ritter, Franco D’ovidio, Thalachallour Mohanakumar, G. Alexander PattersonAbstract:Abstract Background . Gene transfer into the donor Graft has been demonstrated to be feasible in reducing ischemia-reperfusion injury and Rejection in Lung transplantation. This study was undertaken to determine whether intramuscular gene transfer into the recipient can also reduce subsequent Lung Graft Rejection. Methods . Brown Norway rats served as donors and F344 rats as recipients. Recipient animals were injected with 10 10 plaque-forming units of adenovirus encoding active transforming growth factor β1 (group I, n=6), β-galactosidase as adenoviral controls (group II, n=6), or normal saline without adenovirus (group III, n=6) into both gluteus muscles 2 days before transplantation. Gene expression was confirmed by enzyme-linked immunosorbent assay. Graft function was assessed on postoperative day 5. Results . Successful gene transfection and expression were confirmed by the presence of active transforming growth factor β1 protein in muscle and plasma. Oxygenation was significantly improved in group I (group I vs II and III, 353.6 ± 63.0 mm Hg vs 165.7 ± 39.9 and 119.1 ± 41.5 mm Hg; p = 0.02 and 0.004). The muscle transfected with the transforming growth factor β1 showed granulation tissue with fibroblast accumulation. Conclusions . Intramuscular adenovirus-mediated gene transfer of active transforming growth factor β1 into the recipients attenuates acute Lung Rejection as manifested by significantly improved oxygenation in transplanted Lung alloGrafts. This intramuscular transfection approach as a cytokine therapy is feasible in transplantation and may be useful in reducing Rejection as well as reperfusion injury.
Jon H. Ritter - One of the best experts on this subject based on the ideXlab platform.
-
Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 ameliorates acute Lung Graft Rejection
The Journal of thoracic and cardiovascular surgery, 2005Co-Authors: Takashi Suda, Niccolò Daddi, Tsutomu Tagawa, Samer A. Kanaan, Benjamin D. Kozower, Jon H. Ritter, G. Alexander PattersonAbstract:Objective Multiple gene transfer might permit modulation of concurrent biochemical pathways involved in acute Lung Graft Rejection. We investigated whether gene cotransfection into the recipient reduces acute Lung Graft Rejection. Methods Brown Norway rats were used as donors, and F344 rats were used as recipients. Recipient animals were injected with saline (groups I/VI) or 1 × 10 10 pfu of adenovirus encoding β-galactosidase (groups II/VII), transforming growth factor β1 (groups III/VIII), interleukin 10 (groups IV/IX), or both transforming growth factor β1 and interleukin 10 (groups V/X) into both leg muscles 2 days before transplantation (groups I-V) or at the time of harvest (groups VI-X). The Kruskal-Wallis test for Rejection score and 1-way analysis of variance were used to compare groups. Results Oxygenation was significantly improved in the cotransfected groups treated 2 days before transplantation and at the time of harvest. Rejection scores were also reduced in the cotransfected groups. In group V cotransfection suppressed endogenous interleukin 2 but not interferon γ and tumor necrosis factor α. Conclusion Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 suppressed interleukin 2 expression and provided a synergistic effect that reduced acute Lung Graft Rejection. This approach might be applied to the clinical setting because transplant recipients could be treated at the time of implantation.
-
Recipient intramuscular gene transfer of active transforming growth factor-β1 attenuates acute Lung Rejection
The Annals of thoracic surgery, 2001Co-Authors: Takashi Suda, Niccolò Daddi, Jon H. Ritter, Franco D’ovidio, Thalachallour Mohanakumar, G. Alexander PattersonAbstract:Abstract Background . Gene transfer into the donor Graft has been demonstrated to be feasible in reducing ischemia-reperfusion injury and Rejection in Lung transplantation. This study was undertaken to determine whether intramuscular gene transfer into the recipient can also reduce subsequent Lung Graft Rejection. Methods . Brown Norway rats served as donors and F344 rats as recipients. Recipient animals were injected with 10 10 plaque-forming units of adenovirus encoding active transforming growth factor β1 (group I, n=6), β-galactosidase as adenoviral controls (group II, n=6), or normal saline without adenovirus (group III, n=6) into both gluteus muscles 2 days before transplantation. Gene expression was confirmed by enzyme-linked immunosorbent assay. Graft function was assessed on postoperative day 5. Results . Successful gene transfection and expression were confirmed by the presence of active transforming growth factor β1 protein in muscle and plasma. Oxygenation was significantly improved in group I (group I vs II and III, 353.6 ± 63.0 mm Hg vs 165.7 ± 39.9 and 119.1 ± 41.5 mm Hg; p = 0.02 and 0.004). The muscle transfected with the transforming growth factor β1 showed granulation tissue with fibroblast accumulation. Conclusions . Intramuscular adenovirus-mediated gene transfer of active transforming growth factor β1 into the recipients attenuates acute Lung Rejection as manifested by significantly improved oxygenation in transplanted Lung alloGrafts. This intramuscular transfection approach as a cytokine therapy is feasible in transplantation and may be useful in reducing Rejection as well as reperfusion injury.
Niccolò Daddi - One of the best experts on this subject based on the ideXlab platform.
-
Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 ameliorates acute Lung Graft Rejection
The Journal of thoracic and cardiovascular surgery, 2005Co-Authors: Takashi Suda, Niccolò Daddi, Tsutomu Tagawa, Samer A. Kanaan, Benjamin D. Kozower, Jon H. Ritter, G. Alexander PattersonAbstract:Objective Multiple gene transfer might permit modulation of concurrent biochemical pathways involved in acute Lung Graft Rejection. We investigated whether gene cotransfection into the recipient reduces acute Lung Graft Rejection. Methods Brown Norway rats were used as donors, and F344 rats were used as recipients. Recipient animals were injected with saline (groups I/VI) or 1 × 10 10 pfu of adenovirus encoding β-galactosidase (groups II/VII), transforming growth factor β1 (groups III/VIII), interleukin 10 (groups IV/IX), or both transforming growth factor β1 and interleukin 10 (groups V/X) into both leg muscles 2 days before transplantation (groups I-V) or at the time of harvest (groups VI-X). The Kruskal-Wallis test for Rejection score and 1-way analysis of variance were used to compare groups. Results Oxygenation was significantly improved in the cotransfected groups treated 2 days before transplantation and at the time of harvest. Rejection scores were also reduced in the cotransfected groups. In group V cotransfection suppressed endogenous interleukin 2 but not interferon γ and tumor necrosis factor α. Conclusion Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 suppressed interleukin 2 expression and provided a synergistic effect that reduced acute Lung Graft Rejection. This approach might be applied to the clinical setting because transplant recipients could be treated at the time of implantation.
-
Recipient intramuscular gene transfer of active transforming growth factor-β1 attenuates acute Lung Rejection
The Annals of thoracic surgery, 2001Co-Authors: Takashi Suda, Niccolò Daddi, Jon H. Ritter, Franco D’ovidio, Thalachallour Mohanakumar, G. Alexander PattersonAbstract:Abstract Background . Gene transfer into the donor Graft has been demonstrated to be feasible in reducing ischemia-reperfusion injury and Rejection in Lung transplantation. This study was undertaken to determine whether intramuscular gene transfer into the recipient can also reduce subsequent Lung Graft Rejection. Methods . Brown Norway rats served as donors and F344 rats as recipients. Recipient animals were injected with 10 10 plaque-forming units of adenovirus encoding active transforming growth factor β1 (group I, n=6), β-galactosidase as adenoviral controls (group II, n=6), or normal saline without adenovirus (group III, n=6) into both gluteus muscles 2 days before transplantation. Gene expression was confirmed by enzyme-linked immunosorbent assay. Graft function was assessed on postoperative day 5. Results . Successful gene transfection and expression were confirmed by the presence of active transforming growth factor β1 protein in muscle and plasma. Oxygenation was significantly improved in group I (group I vs II and III, 353.6 ± 63.0 mm Hg vs 165.7 ± 39.9 and 119.1 ± 41.5 mm Hg; p = 0.02 and 0.004). The muscle transfected with the transforming growth factor β1 showed granulation tissue with fibroblast accumulation. Conclusions . Intramuscular adenovirus-mediated gene transfer of active transforming growth factor β1 into the recipients attenuates acute Lung Rejection as manifested by significantly improved oxygenation in transplanted Lung alloGrafts. This intramuscular transfection approach as a cytokine therapy is feasible in transplantation and may be useful in reducing Rejection as well as reperfusion injury.
Tsutomu Tagawa - One of the best experts on this subject based on the ideXlab platform.
-
Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 ameliorates acute Lung Graft Rejection
The Journal of thoracic and cardiovascular surgery, 2005Co-Authors: Takashi Suda, Niccolò Daddi, Tsutomu Tagawa, Samer A. Kanaan, Benjamin D. Kozower, Jon H. Ritter, G. Alexander PattersonAbstract:Objective Multiple gene transfer might permit modulation of concurrent biochemical pathways involved in acute Lung Graft Rejection. We investigated whether gene cotransfection into the recipient reduces acute Lung Graft Rejection. Methods Brown Norway rats were used as donors, and F344 rats were used as recipients. Recipient animals were injected with saline (groups I/VI) or 1 × 10 10 pfu of adenovirus encoding β-galactosidase (groups II/VII), transforming growth factor β1 (groups III/VIII), interleukin 10 (groups IV/IX), or both transforming growth factor β1 and interleukin 10 (groups V/X) into both leg muscles 2 days before transplantation (groups I-V) or at the time of harvest (groups VI-X). The Kruskal-Wallis test for Rejection score and 1-way analysis of variance were used to compare groups. Results Oxygenation was significantly improved in the cotransfected groups treated 2 days before transplantation and at the time of harvest. Rejection scores were also reduced in the cotransfected groups. In group V cotransfection suppressed endogenous interleukin 2 but not interferon γ and tumor necrosis factor α. Conclusion Recipient intramuscular cotransfection of transforming growth factor β1 and interleukin 10 suppressed interleukin 2 expression and provided a synergistic effect that reduced acute Lung Graft Rejection. This approach might be applied to the clinical setting because transplant recipients could be treated at the time of implantation.
